Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Running, not enrolling · Phase 2

Conditions studied: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer

In brief

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. (CRC and melenoma cohorts are now closed to new patients)

Key facts

Study ID

NCT04291105

Run by

Vyriad, Inc.

People needed

87

Starts

2020-04-24

Expected to finish

2026-12-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California, United States
• Yale University — New Haven, Connecticut, United States
• University of Miami — Miami, Florida, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Billings Clinic Montana Cancer Consortium — Billings, Montana, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• University of Cincinnati Medical Center — Cincinnati, Ohio, United States
• Sanford Cancer Center — Sioux Falls, South Dakota, United States
• Hospital Sao Rafael — Salvador, BR, Brazil
• INCA — Rio de Janeiro, Rio de Janeiro, Brazil
• Hospital Moinhos de Vento — Porto Alegre, Rio Grande do Sul, Brazil
• Hospital de Amor de Barretos — Barretos, São Paulo, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.